EN | UA
EN | UA

Help Support

Back

Real-world study: Tofacitinib effective for patients with psoriatic arthritis and enthesitis

Psoriatic arthritis Psoriatic arthritis
Psoriatic arthritis Psoriatic arthritis

What's new?

Tofacitinib has an encouraging retention rate in people with psoriatic arthritis with enthesitis unresponsive to other treatments (such as DMARDs), with manageable safety profiles.

In a recent real-life study of patients with psoriatic arthritis (PsA), Tofacitinib exhibited a reasonably good retention rate in these patients who have not responded well to other treatments. Ignacio Braña et al. aimed to investigate the persistence and safety of Tofacitinib in real-world conditions.

The study involved 72 PsA patients who received a minimum of single dose of Tofacitinib. Notably, more than 70% of these patients had already undergone three or more lines of therapy before starting Tofacitinib. Results from the study revealed that Tofacitinib exhibited a good retention rate, with a median survival of 13 months. Furthermore, the one-year retention rate was found to be 52.7%. Importantly, the survival of Tofacitinib was not significantly influenced by factors such as sex, duration of the disease or comorbidities. Younger patients and those experiencing enthesitis, were less likely to stop taking this therapy, suggesting Tofacitinib to be mainly beneficial for patients with refractory PsA and enthesitis.

In terms of safety, the study reported an overall adverse event rate of 52.9 per 100 person-years, with the majority of adverse events occurring within the first 6 months of the treatment, concluded Braña.

Source:

The Journal of Rheumatology

Article:

Patients with psoriatic arthritis-related enthesitis are more likely to persist on Tofacitinib under real-life conditions

Authors:

Ignacio Braña et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: